Exelixis Inc Operating Lease, Payments
Exelixis Inc (EXEL) reported Operating Lease, Payments of $25.61 million for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-02-10
- Exelixis Inc operating lease, payments for the quarter ending 2020-01-03 was $800.00K, a 33.33% increase year-over-year.
- Exelixis Inc operating lease, payments for the quarter ending 2019-09-27 was $700.00K.
- Exelixis Inc operating lease, payments for the quarter ending 2018-12-28 was $600.00K.
- Exelixis Inc operating lease, payments for fiscal 2026 was $25.61M, a 2.76% decline from fiscal 2025.
- Exelixis Inc operating lease, payments for fiscal 2025 was $26.34M, a 34.67% increase from fiscal 2023.
- Exelixis Inc operating lease, payments for fiscal 2023 was $19.56M, a 71.12% increase from fiscal 2022.
- Exelixis Inc operating lease, payments for fiscal 2022 was $11.43M, a 128.60% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|
| 2026-01-02 | $25.61M 10-K · filed 2026-02-10 | ||||
| 2025-01-03 | $26.34M 10-K · filed 2026-02-10 | ||||
| 2023-12-29 | $19.56M 10-K · filed 2026-02-10 | $19.60M 10-K · filed 2024-02-06 | |||
| 2022-12-30 | $11.43M 10-K · filed 2025-02-11 | $11.40M 10-K · filed 2023-02-07 | |||
| 2021-12-31 | $5.00M 10-K · filed 2024-02-06 | ||||
| 2021-01-01 | $4.60M 10-K · filed 2023-02-07 | ||||
| 2020-01-03 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $1.50M derived: sum of 2 quarters · filed 2022-02-18 | $2.90M 10-K · filed 2022-02-18 | ||
| 2019-09-27 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $2.10M 10-Q · filed 2019-10-30 | |||
| 2019-06-28 | $1.40M 10-Q · filed 2019-07-31 | ||||
| 2018-12-28 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $3.90M 10-K · filed 2019-02-22 | |||
| 2018-09-28 | $3.30M 10-Q · filed 2018-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |